Stockscreener 앱 받기
61.72
0.49%
0.30
전일 마감가:
$61.42
열려 있는:
$61
하루 거래량:
271.77K
Relative Volume:
0.36
시가총액:
$2.97B
수익:
-
순이익/손실:
$-86.97M
주가수익비율:
-25.52
EPS:
-2.4189
순현금흐름:
$-81.88M
1주 성능:
-2.03%
1개월 성능:
-12.70%
6개월 성능:
+97.13%
1년 성능:
+377.71%
1일 변동 폭
$60.59
$62.73
1주일 범위
$58.80
$63.04
52주 변동 폭
$9.63
$72.64
Mbx Biosciences Inc Stock (MBX) Company Profile
명칭
Mbx Biosciences Inc
전화
(317) 989-3100
주소
11711 N. MERIDIAN STREET, CARMEL
Compare MBX vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MBX
Mbx Biosciences Inc
|
61.72 | 3.20B | 0 | -86.97M | -81.88M | -2.4189 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Mbx Biosciences Inc Stock (MBX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-28 | 개시 | Barclays | Overweight |
| 2025-12-04 | 개시 | Goldman | Sell |
| 2025-11-04 | 개시 | TD Cowen | Buy |
| 2025-10-15 | 개시 | Truist | Buy |
| 2025-08-15 | 재개 | Jefferies | Buy |
| 2025-08-05 | 개시 | Mizuho | Outperform |
| 2025-07-16 | 개시 | Oppenheimer | Outperform |
| 2025-04-10 | 개시 | Citizens JMP | Mkt Outperform |
| 2024-10-08 | 개시 | Guggenheim | Buy |
| 2024-10-08 | 개시 | JP Morgan | Overweight |
| 2024-10-08 | 개시 | Jefferies | Buy |
| 2024-10-08 | 개시 | Stifel | Buy |
모두보기
Mbx Biosciences Inc 주식(MBX)의 최신 뉴스
MBX BIOSCIENCES, INC. : JP MORGAN RESUMES COVERAGE WITH OVERWEIGHT RATING; TARGET PRICE $88 - Bitget
JPMorgan Chase & Co. Initiates Coverage on MBX Biosciences (NASDAQ:MBX) - MarketBeat
Deep Track Capital Reduces MBX Biosciences Stake in Strategic Pr - GuruFocus
MBX (MBX) Move: Finishes 2.76% Lower at $66.51 on the Day; Technical View: the Supplied Trading Band Runs From $63.18 to $69.84 on the DayMean Reversion Trade - Vinanet
MBX (MBX) Snapshot: Finishes 0.13% Lower at $66.44 on the Day; Boundary Watch: $63.12 and $69.76 Define the Nearby Reference Levels for the Current SessionBollinger Squeeze - Vinanet
MBX Biosciences (NASDAQ: MBX) insider to sell 3,745 shares - Stock Titan
MBX Biosciences (MBX) Edges Lower to $68.12, Consolidating Between Support and ResistanceZigzag Correction - vinanet.vn
MBX Biosciences Inc (MBX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
California State Teachers Retirement System Purchases 21,011 Shares of MBX Biosciences, Inc. $MBX - MarketBeat
Deep Track Capital reports 3.64% MBX Biosciences (MBX) stake in 13G/A - Stock Titan
Stifel Maintains MBX Biosciences(MBX.US) With Buy Rating, Raises Target Price to $70 - Moomoo
MBX Biosciences (MBX) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
Frazier funds detail 10.8% MBX Biosciences stake (MBX) in ownership update - Stock Titan
OrbiMed trims MBX Biosciences (MBX) position to 6.4% after share sales - Stock Titan
Truist Adjusts Price Target on MBX Biosciences to $88 From $70, Maintains Buy Rating - Moomoo
MBX Biosciences, Inc. $MBX Stock Holdings Raised by The Manufacturers Life Insurance Company - MarketBeat
LifeSci Capital Maintains MBX Biosciences(MBX.US) With Buy Rating, Maintains Target Price $121 - moomoo.com
MBX Biosciences (NASDAQ:MBX) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Mizuho Securities Maintains MBX Biosciences(MBX.US) With Buy Rating, Maintains Target Price $91 - Moomoo
MBX SWOT Analysis: Financial Challenges and Growth Potential Rev - GuruFocus
Barclays Maintains MBX Biosciences(MBX.US) With Buy Rating, Raises Target Price to $88 - Moomoo
MBX Biosciences (MBX) Stock Analysis: Strong Buy Ratings and Significant Upside Potential - DirectorsTalk Interviews
MBX Biosciences, Inc. Stock 12‑Month Price Target Raised to $84.8, Implies 26% Upside - TradingView
MBX Biosciences Shares Lower After Q2 Loss Widens - marketscreener.com
MBX Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
MBX Biosciences, Inc. reports results for the quarter ended June 30Earnings Summary - tradingview.com
Earnings Flash (MBX) MBX Biosciences Posts Q2 Net Loss $0.78 a Share, vs. FactSet Est of $0.63 Loss - marketscreener.com
MBX Biosciences posts Q2 loss, advances obesity pipeline By Investing.com - Investing.com Australia
MBX Biosciences posts Q2 loss, advances obesity pipeline - Investing.com
MBX Biosciences Reports Second Quarter 2026 Financial Results and Corporate Highlights - The Manila Times
MBX Biosciences posts $37.1 million Q2 net loss - Quiver Quantitative
Earnings Flash (MBX) MBX Biosciences Posts Q2 Net Loss $0.78 a Share, Vs. FactSet Est of $0.63 Loss - Moomoo
MBX Biosciences 2Q 2026: Net loss $(37.1M), EPS $(0.78) — 10-Q Summary - TradingView
MBX: Q2 net loss increased to $37.1M as R&D spending rose; cash reserves support operations into 2029 - tradingview.com
MBX Biosciences (Nasdaq: MBX) widens Q2 loss but holds $418.6M cash - Stock Titan
MBX: Advanced pipeline, strong cash position, and expanded obesity portfolio despite higher net loss - TradingView
Insider Selling: MBX Biosciences (NASDAQ:MBX) Insider Sells $24,334.90 in Stock - MarketBeat
MBX Biosciences (MBX) CMO sells 370 shares to cover RSU taxes - Stock Titan
MBX: Advancing precision peptide therapies for endocrine and obesity indications with strong clinical momentum - TradingView
MBX Q2'26 Earnings: EPS estimate is (0.63) USD - TradingView
MBX Biosciences (NASDAQ:MBX) Reaches New 52-Week HighStill a Buy? - marketbeat.com
Mbx Biosciences stock hits all-time high of 69.5 USD By Investing.com - Investing.com India
MBX (MBX) affiliate plans to sell 936 vested common shares after prior sale - Stock Titan
Salomon Azoulay plans 370-share sale of MBX (NASDAQ: MBX) - Stock Titan
Mbx Biosciences stock hits all-time high of 69.5 USD - Investing.com
MBX Biosciences, Inc. (MBX) awards CFO 130,000 options and 28,000 RSUs - Stock Titan
MBX Biosciences, Inc. (MBX) grants CEO major option and RSU awards - Stock Titan
Swiss National Bank Invests $1.32 Million in MBX Biosciences, Inc. $MBX - MarketBeat
MBX Biosciences, Inc. $MBX Shares Purchased by Stempoint Capital LP - MarketBeat
MBX Biosciences (NASDAQ:MBX) Sets New 52-Week High on Analyst Upgrade - MarketBeat
MBX Biosciences (NASDAQ:MBX) Given New $91.00 Price Target at Mizuho - MarketBeat
Mbx Biosciences Inc (MBX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Mbx Biosciences Inc 주식 (MBX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Azoulay Salomon | Chief Medical Officer |
Aug 04 '26 |
Sale |
65.77 |
370 |
24,335 |
14,399 |
0.86%
0.31%
자본화:
|
볼륨(24시간):